Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Bone spicule pigmentation of the retina, Nyctalopia, and Progressive visual loss; and common findings: Macular atrophy and Attenuation of retinal blood vessels. 8 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Blindness, Macular atrophy, Attenuation of retinal blood vessels |
IFT140 encodes intraflagellar transport 140 (1,462 aa). Component of the IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs). Highest expression in Thyroid (59.8 TPM) and Testis (47.9 TPM).
Retinitis pigmentosa 80 is associated with mutations in the IFT140 gene on chromosome 16.
IFT140 is classified as a druggable target with score 0.0.
Genetic testing for IFT140 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 80 has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 2 common features.
No clinical trials have been registered for retinitis pigmentosa 80.
60 publications have been identified in PubMed for retinitis pigmentosa 80. Research spans Epidemiology / Natural History (33%), Gene Therapy / Novel Therapeutics (17%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 20 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 9:40 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Bones and joints |
1 |
Bone spicule pigmentation of the retina |
Brain and nerves | 1 | Global developmental delay |
Arms and legs | 1 | Cone-shaped epiphyses of the phalanges of the hand |
Muscles | 1 | Macular atrophy |
Age of onset: childhood.
New treatment approaches
10 |
17% |
Laboratory research | 9 | 15% |
Testing and diagnosis research | 8 | 13% |
Patient case studies | 6 | 10% |
Clinical study results | 4 | 7% |
Research summaries | 3 | 5% |
Hiraoka M (2026). [PMID: 42212888](https://pubmed.ncbi.nlm.nih.gov/42212888/). *Transl Vis Sci Technol*. [Diagnostic / Biomarker]
Reuter P (2026). [PMID: 42192302](https://pubmed.ncbi.nlm.nih.gov/42192302/). *Mol Med*. [Review / Meta-Analysis]
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Carpenter E (2026). [PMID: 41632744](https://pubmed.ncbi.nlm.nih.gov/41632744/). *Ophthalmic Res*. [Clinical Trial Publication]
Jony MJ (2026). [PMID: 41944104](https://pubmed.ncbi.nlm.nih.gov/41944104/). *Curr Drug Deliv*. [Gene Therapy / Novel Therapeutics]
Al-Moujahed A (2026). [PMID: 41891913](https://pubmed.ncbi.nlm.nih.gov/41891913/). *Ophthalmic Surg Lasers Imaging Retina*. [Epidemiology / Natural History]
He Y (2026). [PMID: 41507979](https://pubmed.ncbi.nlm.nih.gov/41507979/). *J Transl Med*. [Gene Therapy / Novel Therapeutics]
Eriksen KO (2026). [PMID: 40977613](https://pubmed.ncbi.nlm.nih.gov/40977613/). *Acta Ophthalmol*. [Gene Therapy / Novel Therapeutics]
Papp KM (2026). [PMID: 41547546](https://pubmed.ncbi.nlm.nih.gov/41547546/). *Can J Ophthalmol*. [Epidemiology / Natural History]
Aychoua N (2026). [PMID: 41296346](https://pubmed.ncbi.nlm.nih.gov/41296346/). *JAMA Ophthalmol*. [Basic Science / Preclinical]